B · Normal
[Huadong Medicine: Wholly-owned subsidiary HDM4002 injection was approved for clinical trials] On November 18, Huadong Medicine (000963.SZ) announced that the company's wholly-owned subsidiary Sino-American Huadong received the "Drug Clinical Trial Approval Notice" approved and issued by the National Medical Products Administration, and the clinical trial application for HDM4002 injection submitted by Sino-US Huadong was approved. This drug is a new Class 1 therapeutic biological product, and is indicated for the treatment of adult patients with primary immunoglobulin A nephropathy who are at risk of disease progression. HDM4002 injection is a Class 1 new biological drug developed by Sino-US Huadong and owns global intellectual property rights. It is a bispecific antibody drug that dual-targets complement factor B and mannan-binding lectin-related serine protease-2. The approval of this clinical trial will enhance the company's core competitiveness in the field of autoimmune therapy and will not have a significant impact on recent performance.
Comments